Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201940 · ClinicalTrials.gov registry record · Phase 3
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 741
- Enrollment target
NCT02201940: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT02201940 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 741 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02201940, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 741 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis C virus (HCV) infection.
Primary Outcome
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Interventions
- DRUG Placebo
- DRUG SOF/VEL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
What the finished NCT02201940 record still lists
NCT02201940 is an interventional study that assigns participants to a tested intervention. The registered 741 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02201940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02201940 about?
NCT02201940 is a clinical study titled "Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection". The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis C virus (HCV) infection.
What is the current status of trial NCT02201940?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 741 participants. The study started on 2014-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02201940?
The interventions under investigation include: Placebo (DRUG), SOF/VEL (DRUG).
Who is sponsoring clinical trial NCT02201940?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02201940's enrollment target sits among peer trials
741 476th of 2000 higher than 1,524 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia